Neurol. praxi. 2025;26(6):447-451 | DOI: 10.36290/neu.2025.021

Bolesti hlavy - nové možnosti léčby

MUDr. Pavel Řehulka, Ph.D.
I. neurologická klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně

Received: March 14, 2025; Revised: March 14, 2025; Accepted: March 14, 2025; Prepublished online: March 14, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Řehulka P. Bolesti hlavy - nové možnosti léčby. Neurol. praxi. 2025;26(6):447-451. doi: 10.36290/neu.2025.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 15.12.2026

    References

    1. Al-Hassany L, Boucherie DM, Creeney H, et al. Future targets for migraine treatment beyond CGRP. J Headache Pain. 2023;24(1):76. Published 2023 Jun 28. doi:10.1186/s10194-023-01567-4. Go to original source... Go to PubMed...
    2. Ashina H, Iljazi A, Al-Khazali HM, et al. Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. J Headache Pain. 2020;21(1):62. Published 2020 Jun 3. doi:10.1186/s10194-020-01136-z Go to original source... Go to PubMed...
    3. De Petrocellis L, Vellani V, Schiano-Moriello A, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther. 2008;325(3):1007-1015. doi:10.1124/jpet.107.134809. Go to original source... Go to PubMed...
    4. Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: A review of the mode of action in migraine. Acta Neurol Scand. 2018;137(5):442-451. doi:10.1111/ane.12906. Go to original source... Go to PubMed...
    5. Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. Cephalalgia. 2020;40(9):935-948. doi:10.1177/0333102420905321. Go to original source... Go to PubMed...
    6. Fricová J, Kozák J, Lejčko J, et al. Metodické pokyny pro farmakoterapii chronické bolesti. Bolest. 2022;25(Suppl. 1):1-44.
    7. Goadsby PJ, Dodick DW, Leone M, et al. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med. 2019;381(2):132-141. doi:10.1056/NEJMoa1813440. Go to original source... Go to PubMed...
    8. Kopruszinski CM, Thornton P, Arnold J, et al. Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Cephalalgia. 2020;40(14):1535-1550. doi:10.1177/0333102420966581. Go to original source... Go to PubMed...
    9. Krajnc N, Itariu B, Macher S, et al. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023;24(1):89. Published 2023 Jul 18. doi:10.1186/s10194-023-01631-z. Go to original source... Go to PubMed...
    10. Krivoshein G, Rivera-Mancilla E, MaassenVanDenBrink A, et al. Sex difference in TRPM3 channel functioning in nociceptive and vascular systems: an emerging target for migraine therapy in females?. J Headache Pain. 2025;26(1):40. Published 2025 Feb 24. doi:10.1186/s10194-025-01966-9. Go to original source... Go to PubMed...
    11. Landa L, Juřica J, Trojan V, et al. Léčebné konopí a jeho význam pro současnou medicínu. Anest. intenziv. Med. 2023;34(1):8-14. doi: 10.36290/aim.2023.003. Go to original source...
    12. Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-1830. doi:10.1093/brain/awad003. Go to original source... Go to PubMed...
    13. Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun. 1990; 170(2): 643-648. doi: 10.1016/0006-291x(90)92 140-u. Go to original source...
    14. National Library of Medicine [online]. ClinicalTrials.gov: ©2025 [cit. 9.3.2025]. Pediatric Migraine. Available from: https://clinicaltrials.gov/search?cond=pediatric%20migraine.
    15. National Library of Medicine [online]. ClinicalTrials.gov: ©2025 [cit. 9.3.2025]. Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant. Available from: https://clinicaltrials.gov/study/NCT05046613?cond=migraine%20maternal&rank=1.
    16. National Library of Medicine [online]. ClinicalTrials.gov: ©2025 Emgality for Migraine in Breast Milk [cit. 9.3.2025]. Available from: https://clinicaltrials.gov/study/NCT06085144?cond=migraine&term=breastfeeding&rank=1.
    17. National Library of Medicine [online]. ClinicalTrials.gov: ©2025 Erenumab [cit. 9.3.2025]. Available from: https://www.clinicaltrials.gov/search?intr=Erenumab.
    18. Schott Andersen AS, Maarbjerg S, Noory N, et al. Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lancet Neurol. 2022;21(11):994-1003. doi:10.1016/S1474-4422(22)00294-0. Go to original source... Go to PubMed...
    19. Schuster NM, Wallace MS, Marcotte TD, et al. Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial. Preprint. medRxiv. 2024;2024.02.16.24302843. Published 2024 Feb 18. doi:10.1101/2024.02.16.24302843. Go to original source... Go to PubMed...
    20. Státní ústav pro kontrolu léčiv [online]. SÚKL ©2025 [cit. 9.3.2025]. Konopí pro léčebné použití. Available from: https://sukl.gov.cz/media/sukl-pro-media/konopi-pro-lecebne-pouziti/.
    21. Tepper SJ, Dodick DW, Lanteri-Minet M, et al. Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial. JAMA Neurol. Published online September 16. 2024. doi:10.1001/jamaneurol.2024.3043. Go to original source... Go to PubMed...
    22. Weiss V, Haršány M, Řehulka P. Pituitární adenylátcyklázu aktivující polypeptid (PACAP) a jeho role v patofyziologii migrény. Česká a slovenská neurologie a neurochirurgie. 2023; 86/119:177-183. Go to original source...
    23. Yiangou A, Mitchell JL, Fisher C, et al. Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation. Headache. 2021;61(1):157-169. doi:10.1111/head.14026. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.